ADCS/NIA PROTOCOL ACD-015: SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 从动物模型和细胞培养系统的实验室研究、观察性流行病学研究和小型临床试验中有令人信服的证据表明，降低胆固醇可能会减少阿尔茨海默病（AD）的病理学。 这些研究表明，胆固醇水平升高可能与淀粉样蛋白沉积和认知功能有关，降低这些水平可能会减少淀粉样蛋白并导致认知益处。 辛伐他汀是HMG-CoA还原酶抑制剂。 在冠心病和高胆固醇血症患者中，适用于降低以下风险：1）通过降低冠状动脉死亡降低总死亡率，2）非致死性心肌梗死，3）接受心肌血运重建术和4）卒中或短暂性脑缺血发作。 这项研究背后的假设是，辛伐他汀将显着减少AD的临床进展，并将显示出有益的影响，超过安慰剂的措施，日常生活活动，精神和行为症状，生活质量和经济措施。 本研究的人群为400例无高胆固醇血症的AD受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is compelling evidence from laboratory research in animal model and cell culture systems, observational epidemiological studies, and small clinical trials, that lowering cholesterol may reduce the pathology of Alzheimer's Disease (AD). These studies indicate that elevated cholesterol levels may be related to amyloid deposition and cognitive function and that lowering these levels may reduce amyloid and lead to cognitive benefit. Simvastatin is an HMG-CoA reductase inhibitor. In patients with coronary heart disease and hypercholesterolemia, it is indicated to reduce the risk 1) of total mortality by reducing coronary death, 2) of non-fatal myocardial infarction, 3) for undergoing myocardial revascularization procedures and 4) of stroke or transient ischemic attack. The hypothesis behind this study is that simvastatin will significantly reduce the clinical progression of AD and will show beneficial effects over placebo on measures of activities of daily living, psychiatric and behavioral symptoms, quality of life and economic measures. The population for this study will be 400 subjects with AD who do not have hypercholesterolemia.